Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two full years alongside radiation can meaningfully reduce the chance the ...

Men diagnosed with high-risk localized prostate cancer now have trial-level evidence that adding the drug apalutamide to ...

In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.

A partitioned-survival lifetime model (2025 USD) compared ADT alone with seven intensification strategies across PFS, post-progression, and death, using published survival curves and literature-based ...

A quality improvement study analyzed the value of advanced telehealth delivery methods during prostate cancer management.

In this long-term follow-up to the phase 2 ARTO trial, researchers analyzed survival outcomes in patients with CRPC treated with metastasis-directed therapy.

Men with prostate cancer who were treated with the GnRH agonist leuprolide had significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix.

Erratum: Beyond Infusion: Real-World Insights Into Infusion-Related Reactions in Monoclonal Antibody Therapy The 2022 AUA/ASTRO guidelines recommend 18-36 months of androgen deprivation therapy (ADT) ...

Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...

—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

Prostate cancer is the most common malignancy among men, with over 160,000 new cases diagnosed annually in the United States. Although advances in surgery, radiotherapy, and hormone therapy have ...